Newsletter
| Promoter: | PennyStockLocks.com | Paying Party: | Ramos & Ramos LLC |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| AXXE | $15000 | 40320 |
| Max Profit: 41.41 % | Gain at close: 7.07 % | |
| *We think that this promoter is a part of a group of promoters. | ||
|
Members, We have just found an amazing bottom'd chart pharmaceutical bounce opportunity for you! Please turn your immediate attention to AXXE (Axxess Pharma Inc.). AXXE took an extremely opportunistic dip last week, and looks to have leveled out at its current PPS of $0.50! AXXE was trading over a $1.00 just last week, and the upside potential at the current price is just incredible! AXXE's recent price swing has us believing that this pharmaceutical company is extremely volatile in a good way! This is important because AXXE released huge after market news that it has yet to be traded on! The company announced they have signed an agreement with a leading Mexican pharmaceutical company, Industria Farmaceutica Andromaco, S.A. de C.V. Under the agreement, AXXE's Soropon, will be marketed in Mexico by Andromaco. AXXE has also secured the rights to market in Canada, several of Andromaco's market leading baby-care products.
AXXE's Soropon, a medicated shampoo for the treatment of cradle cap in infants and a severe form of dandruff in seniors (Seborrheic dermatitis), fits with Andromaco's core product line and is anticipated to generate strong sales.
Dr. Daniel Bagi, President of Axxess Pharma, stated: "With a population three times that of Canada's and a higher birth rate than Canada's, Axxess is extremely pleased with the market possibilities in Mexico for Soropon and we anticipate robust sales for Soropon in Mexico, starting in 2014. Two of Andromaco's baby care products are among the market leaders in Mexico with annual sales in excess of ten million dollars (US). Andromaco also generates sales exporting and selling into the US. These products are manufactured in Andromaco's US FDA-approved facility. Their product offerings in infant skin care will add to our OTC infant skincare product line for the Canadian market."
This is huge news with major revenue implications! This could be the perfect catalyst to get this volatile alert moving in the right direction! How many times have we watched companies explode in value shortly after increased revenue projections were made? A fast moving alert like AXXE could see record gains today on this news alone! We have a feeling that traders are going to be all over this one! Could this be the start of a VERY PROFITALBE +100% RUN UP THE CHARTS! We are urging all members to immediately start their research on AXXE, and be ready early today at 9:30am EST! Please review AXXE'S Chart, latest news, and full profile below:  Company: Axxess Pharma Inc.
SYMBOL: AXXE
Current PPS: $0.50
Outstanding Shares: 39.1M Website: www.axxesspharmainc.com About The Company: Axxess Pharma Inc. (PINKSHEETS: AXXE) is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, - to optimal health management through improved nutritional supplements.
On Monday AXXE an Agreement in Principle to acquire a leading Canadian OTC healthcare company. Upon completion of the acquisition, the company will bring current sales and a valuable IP portfolio to Axxess Pharma.
The Canadian Corporation, based in Toronto, has an attractive IP portfolio including a best-selling, patented, OTC pain relief formula. The company also has a number of unique formulas and world class brand products that Axxess Pharma will be able to immediately leverage, with existing distribution.
The company will also bring a number of experienced executives to Axxess Pharma to assist in growing sales across North America, and online.
New addition to management:
Last week the company announced that Dr. Fred Maese, US Board-Certified Cardiologist and a member of the American College of Cardiology, has joined Axxess Pharma.
Since 1997 Dr. Maese has been practicing adult Cardiology and Internal Medicine in Dallas, Texas with expertise in general clinical cardiology, echocardiography and nuclear cardiology. Dr. Maese also has a large following on his radio shows, which cross over to the Hispanic network 'Univision.'
Daniel Bagi, M.D., President of Axxess Pharma stated: "Dr. Maese brings to AXXESS a wealth of knowledge and experience, running a successful medical practice. He also possesses a strong medical following via his radio shows. Dr. Maese will be a key component in the execution of our Business Plan."
Business Acumen: Dr. Maese was instrumental in the clinical acceptance, widespread use and business models pertaining to the Lap Band procedure for morbidly obese patients with and without cardiovascular disease who had failed conservative medical weight management. Dr. Maese also has significant experience in medical education in both radio and television, with his segment "Breakthrough Medicine" receiving an overwhelming acceptance by the public and peers on the popular show Good Morning Texas. In addition, his radio shows on Univision (a Hispanic population targeted TV channel) in Texas have also focused on an educational format pertinent to the Latin American population. This year he will launch both English and Spanish weekly radio programming on a variety of medical and other topics.
Dr. Maese is also the creator of the MyClinic affordable and convenient primary care model, started in 2011 and now in the expansion phase. This concept of primary care delivery services promotes preventive, acute and chronic care strategies for the whole family in an affordable and convenient fashion. MyClinic is poised to become a leader in the primary and preventive care services for the US population over the next three to five years.
AXXE has also taken huge steps in increasing its brand awareness:
In July the company announced that two time Canadian heavyweight boxing champion Ray Olubowale will be joining Axxess Pharma as spokesperson and corporate ambassador.
Ray brings an illustrious career as a heavyweight boxing champion, winning the Canadian, American, Mexican and North American heavyweight titles. Ray also gives back to the community as a boxing coach with the School of Hard Nox Boxing Academy from 19999 to present. He is also a food nutritionist within the school and works as an educational consultant with Omega Alpha Pharmaceuticals.
With this aggressive marketing initiative, and their latest acquisition news AXXE could be well on its way to a huge increase in revenue!
Don't forget that AXXE is operating in a multi-billion dollar pharmaceutical market.
A recent Report on the US Healthcare Industry predicts the country’s pharmaceutical market value to rise from $359 billion in 2012 to $476 billion in 2020, representing an increase of 33% over the 8 year period.
In fact, certain analysts predict the Global Pharma Market may be valued at nearly $1.6 trillion by 2020!
We are urging all members to add AXXE to their radar immediately and be ready early today at 9:30am EST!
Let's get ready for an exciting day of trading...
Remember the first step to becoming a successful penny stock trader is opening up a brokerage account if you haven't done so already you can start by clicking here. Sincerely, The PennyStockLocks Team P.S. Share the wealth and forward this email to all your fellow traders who have yet to join the fastest growing network of serious traders on the web. AXXESS Pharma Inc. Signs Agreement With Top Mexican Pharmaceutical Company 4:15p ET September 9, 2013 (Market Wire)
Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical and nutritional supplements company, is pleased to announce they have signed an agreement with a leading Mexican pharmaceutical company, Industria Farmaceutica Andromaco, S.A. de C.V.
Under the agreement, Axxess Pharma's product, Soropon, will be marketed in Mexico by Andromaco. Axxess has also secured the rights to market in Canada, several of Andromaco's market leading baby-care products.
Axxess's Soropon, a medicated shampoo for the treatment of cradle cap in infants and a severe form of dandruff in seniors (Seborrheic dermatitis), fits with Andromaco's core product line and is anticipated to generate strong sales.
Dr. Daniel Bagi, President of Axxess Pharma, stated: "With a population three times that of Canada's and a higher birth rate than Canada's, Axxess is extremely pleased with the market possibilities in Mexico for Soropon and we anticipate robust sales for Soropon in Mexico, starting in 2014. Two of Andromaco's baby care products are among the market leaders in Mexico with annual sales in excess of ten million dollars (US). Andromaco also generates sales exporting and selling into the US. These products are manufactured in Andromaco's US FDA-approved facility. Their product offerings in infant skin care will add to our OTC infant skincare product line for the Canadian market."
Mr. Victor Alvarez, CEO of Andromaco, stated: "Andromaco is very pleased to start the process towards Canadian sales with Axxess Pharma for our high-quality infant care products and complete our goal of selling all across North America."
For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.
About Axxess Pharma Inc.: Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, to optimal health management through improved nutritional supplements.
Industria Farmaceutica Andromaco, S.A. de C.V. Andromaco is a well-established Mexican pharmaceutical company with over 80 years in the Mexican market. They have a US FDA-approved state-of-the-art manufacturing facility for creams and ointments and are one of the top 10 Mexican pharmaceutical manufacturers.
----------------------------------------------------- Follow Us On: This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: Pennystocklocks.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Pennystocklocks.com does not provide trading, investment or tax advice, and readers shall not rely on statements by Pennystocklocks.com employees which purport to provide such advice. Full disclaimer can be read at http://www.Pennystocklocks.com/Disclaimer/ |
